Assay News and Research

RSS

Redpoint Bio decreases third quarter net loss to $1.8 million

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the three months and nine months ended September 30, 2010.

9 Nov 2010

Abbott wins 2010 Scrip Awards for business excellence and strong management

Scrip, a leading global pharmaceutical and biotech news organization, honored Abbott with two 2010 Scrip Awards for its business excellence and strong management.

8 Nov 2010

Affymetrix to contribute genotyping data to 1000 Genomes Project

Affymetrix, Inc. today announced that it will contribute genotyping data for a large set of validated rare and common genomic variants to the 1000 Genomes Project. This powerful data consists of genotyping information from more than 2 million single nucleotide polymorphisms (SNPs), and insertions/deletions (indels), many of which were not previously available from any source.

4 Nov 2010

New simple blood test may help diagnose Niemann-Pick type C disease

A fatal genetic disorder that frequently takes years to diagnose may soon be detectable with a simple blood test, researchers at Washington University School of Medicine in St. Louis and the National Institutes of Health (NIH) report this week in Simple blood test may diagnose deadly Niemann-Pick type C disease.

4 Nov 2010

Idaho seeks FDA marketing clearance for FilmArray Respiratory Panel

Idaho Technology, Inc. (ITI) announced today that it has filed a submission with the U.S. Food and Drug Administration for 510(k) clearance to market its FilmArray Respiratory Panel (RP) as an in vitro diagnostic product for patients with symptoms of upper respiratory tract infection.

4 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

New Ovation systems improve nucleic acid extraction from FFPE tissue samples

NuGEN Technologies, the provider of innovative RNA and DNA sample preparation solutions for genomic analysis, today announced the availability of the Ovation WGA FFPE System and the Ovation RNA-Seq FFPE System. These are the first commercially available products designed specifically to enable researchers to utilize next-generation sequencing (NGS) technologies to analyze nucleic acids extracted from Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

3 Nov 2010

Avila presents results of AVL-192 preclinical studies for HCV infection at AASLD Meeting

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, presented results today of preclinical studies that demonstrate its orally-available targeted covalent drug candidate, AVL-192, achieves superior potency against drug-resistant mutations of the Hepatitis C Virus (HCV). These new data were presented today at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) international meeting in Boston, Massachusetts.

3 Nov 2010

NanoString’s nCounter CNV CodeSets help detect genetic copy number variations

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the launch of a novel solution for detecting genetic copy number variations (CNVs) associated with disease susceptibility, drug response and cancer progression.

From NanoString Technologies 2 Nov 2010

New microfluidic in vitro kinase radioassay improves efficiency to detect cancer growth

Inappropriate growth and survival signaling, which leads to the aberrant growth of cancer cells, is a driving force behind tumors. Much of current cancer research focuses on the kinase enzymes whose mutations are responsible for such disregulated signaling, and many successful molecularly targeted anti-cancer therapeutics are directed at inhibiting kinase activity.

2 Nov 2010

National Jewish Health's chronic urticaria diagnostic assay receives US patent

National Jewish Health has received a US patent for a method of detecting autoimmune chronic urticaria, which will help assure many patients that dramatic changes in lifestyle are not needed to treat the condition.

2 Nov 2010

Researchers develop three-dimensional culture that mimics growth patterns of colon cancer stem cells

University of Pittsburgh researchers have devised a three-dimensional system in laboratory culture that mimics the growth patterns of colon cancer stem cells in patients. Their findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron Corporation today reported financial results for the three and nine months ended September 30, 2010.

29 Oct 2010

Gen-Probe third quarter research revenue increases 70% to $3.4 million

Gen-Probe Incorporated today reported financial results for the third quarter of 2010, highlighted by 19% growth in non-GAAP earnings per share (EPS) and 8% growth in product sales and total revenues.

29 Oct 2010

MRI awarded $31M NIH contract to provide chemistry support for National Toxicology Program

Midwest Research Institute (MRI), one of the nation's leading independent research organizations, with more than 65-years of experience in scientific research, has been awarded a $31 million contract from the National Institute of Environmental Health Sciences. Under the 5-year contract, MRI scientists will provide chemical procurement, handling, and analytical chemistry services requested by the National Toxicology Program (NTP) for toxicology studies in progress throughout the U.S.

28 Oct 2010

Epigenomics presents data on Septin9 biomarker clinical study for colorectal cancer at UEGW

Epigenomics AG, the cancer diagnostics company, announced that new data obtained in a clinical study with the Company's proprietary Septin9 biomarker for the blood-based detection of colorectal cancer, were presented yesterday at the 18th United European Gastroenterology Week (UEGW) in Barcelona, Spain.

28 Oct 2010

New computational techniques to overcome obstacles in hard-to-study genes

Scientists have invented methods to scout the human genome's repetitive landscapes, where DNA sequences are highly identical and heavily duplicated. These advances, as reported today in Science, can identify subtle but important differences among people in the number and content of repeated DNA segments.

28 Oct 2010

Evotec, Apeiron Biologics enter collaboration

Evotec AG today announced that it has entered into a collaboration with Apeiron Biologics AG, to initially identify small molecule modulators of DREAM (Downstream Regulatory Element Antagonistic Modulator), a novel target involved in perception of various pain mechanisms. Further projects will be evaluated to potentially expand this cooperation in due course.

27 Oct 2010

Elan 2010 third quarter total revenue decreases 2% to $281.4 million

Elan Corporation, plc today reported its third quarter and first nine months 2010 financial results.

27 Oct 2010

AutoGenomics granted FDA 510(k) clearance for INFINITI CYP2C19 Assay

AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market its INFINITI® CYP2C19 Assay. The test detects 3 genetic variants, *2, *3, *17, of the CYP450 2C19 gene and is to be used on the company's automated molecular testing platform, the INFINITI® Analyzer.

27 Oct 2010